← Browse by Condition
Medical Condition

non hodgkin lymphoma

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, EARLY_Phase 1, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — non hodgkin lymphoma Clinical Trials

How many clinical trials are currently recruiting for non hodgkin lymphoma?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for non hodgkin lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for non hodgkin lymphoma?
non hodgkin lymphoma research spans Phase 1 (4 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a non hodgkin lymphoma clinical trial?
Eligibility criteria for non hodgkin lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
2
Top Sponsors
Fred Hutchinson Cancer Center 1 trial
University of Birmingham 1 trial
Wake Forest University Health Sciences 1 trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1 trial
Jecho Biopharmaceuticals Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT06013423 Phase 2
Recruiting
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Enrollment
54 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
View Trial →
NCT04888741 Phase 2
Recruiting
Methods of T Cell Depletion Trial (MoTD)
Enrollment
400 pts
Location
United Kingdom
Sponsor
University of Birmingham
View Trial →
NCT05595577
Recruiting
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Enrollment
110 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT06398457 EARLY_Phase 1
Recruiting
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Enrollment
8 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca...
View Trial →
NCT07623850 Phase 1
Recruiting
A Phase I Study of JLM019 Injection
Enrollment
115 pts
Location
China
Sponsor
Jecho Biopharmaceuticals Co., ...
View Trial →
NCT06383338 Phase 1
Recruiting
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Enrollment
10 pts
Location
Australia
Sponsor
Murdoch Childrens Research Ins...
View Trial →
NCT05839210
Recruiting
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
Enrollment
140 pts
Location
United States
Sponsor
University of Miami
View Trial →
NCT06026319 Phase 1
Recruiting
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Enrollment
24 pts
Location
United States
Sponsor
Marcela V. Maus, M.D.,Ph.D.
View Trial →

Related Conditions

hodgkin lymphoma (6) acute lymphoblastic leukemia (2) acute myeloid leukemia (2) multiple myeloma (2) myelofibrosis (2) acute leukemia of ambiguous lineage (1) blastic plasmacytoid dendritic cell neoplasm (1) hematopoietic and lymphatic system neoplasm (1) mixed phenotype acute leukemia (1) myelodysplastic syndrome (1) myeloproliferative neoplasm (1) chronic myeloid leukemia bcr abl1 positive (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology